Each tablet contains Sitagliptin 50 mg + Metformin Hydrochloride SR 1000 mg + Glimepiride 2 mg.

SITANORM-GM / DIAPRIDE-SM Tablets combine Sitagliptin (DPP-4 inhibitor), Metformin SR (biguanide), and Glimepiride (sulfonylurea) to provide comprehensive glycaemic control in adults with type 2 diabetes mellitus. Sitagliptin enhances glucose-dependent insulin secretion by increasing incretin hormone activity, Metformin reduces hepatic glucose production and improves insulin sensitivity, while Glimepiride stimulates insulin release from functional pancreatic beta cells. This triple-drug combination offers complementary mechanisms of action for patients inadequately controlled with diet, exercise, or dual antidiabetic therapy.

SITANORM-GM / DIAPRIDE-SM Tablets are indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus.

Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that prolongs the activity of incretin hormones, thereby increasing glucose-dependent insulin secretion and reducing glucagon secretion. Metformin is an antihyperglycaemic agent that lowers hepatic glucose production, decreases intestinal glucose absorption, and enhances peripheral insulin sensitivity. Glimepiride lowers blood glucose primarily by stimulating insulin secretion from functioning pancreatic beta cells. Together, these agents provide complementary actions to improve both fasting and postprandial glycaemic control.

The recommended dosage is one tablet orally once daily, with or without meals. The tablet should be swallowed whole or as directed by the physician.

SITANORM-GM / DIAPRIDE-SM Tablets are contraindicated in patients with renal impairment, known hypersensitivity to sitagliptin, metformin hydrochloride, glimepiride, or any component of the formulation, and in patients with acute or chronic metabolic acidosis, including diabetic ketoacidosis.